NASDAQ:FOMX - Foamix Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $3.87 +0.06 (+1.57 %) (As of 03/20/2019 04:00 PM ET)Previous Close$3.81Today's Range$3.81 - $3.9252-Week Range$3.21 - $7.60Volume168,079 shsAverage Volume383,400 shsMarket Capitalization$210.40 millionP/E Ratio-2.28Dividend YieldN/ABeta1.68 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations primarily for the treatment of moderate-to-severe acne, moderate-to-severe papulo-pustular rosacea, and other skin conditions in the United States and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline, which has completed a double-blind and dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus. The company is also developing FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea; and FDX104 that has completed Phase II clinical trial for the treatment of chemotherapy-induced rash. Foamix Pharmaceuticals Ltd. has development and license agreements with Bayer HealthCare AG; Mylan N.V.; and Actavis Laboratories. The company was founded in 2003 and is headquartered in Rehovot, Israel. Receive FOMX News and Ratings via Email Sign-up to receive the latest news and ratings for FOMX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medicinals & botanicals Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FOMX Previous Symbol CUSIPN/A CIK1606645 Webwww.foamix.com Phone972-8931-6233Debt Debt-to-Equity RatioN/A Current Ratio9.66 Quick Ratio9.66Price-To-Earnings Trailing P/E Ratio-2.28 Forward P/E Ratio-2.56 P/E GrowthN/A Sales & Book Value Annual Sales$3.60 million Price / Sales58.44 Cash FlowN/A Price / Cash FlowN/A Book Value$1.70 per share Price / Book2.28Profitability EPS (Most Recent Fiscal Year)($1.70) Net Income$-74,160,000.00 Net Margins-2,038.64% Return on Equity-104.61% Return on Assets-89.02%Miscellaneous EmployeesN/A Outstanding Shares54,366,000Market Cap$210.40 million Next Earnings Date5/14/2019 (Estimated) OptionableOptionable Foamix Pharmaceuticals (NASDAQ:FOMX) Frequently Asked Questions What is Foamix Pharmaceuticals' stock symbol? Foamix Pharmaceuticals trades on the NASDAQ under the ticker symbol "FOMX." How were Foamix Pharmaceuticals' earnings last quarter? Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) announced its earnings results on Wednesday, November, 7th. The specialty pharmaceutical company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.31) by $0.07. The specialty pharmaceutical company had revenue of $0.87 million for the quarter, compared to analyst estimates of $1.10 million. Foamix Pharmaceuticals had a negative return on equity of 104.61% and a negative net margin of 2,038.64%. View Foamix Pharmaceuticals' Earnings History. When is Foamix Pharmaceuticals' next earnings date? Foamix Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Foamix Pharmaceuticals. What price target have analysts set for FOMX? 4 analysts have issued twelve-month target prices for Foamix Pharmaceuticals' stock. Their forecasts range from $11.00 to $30.00. On average, they expect Foamix Pharmaceuticals' stock price to reach $17.6667 in the next year. This suggests a possible upside of 356.5% from the stock's current price. View Analyst Price Targets for Foamix Pharmaceuticals. What is the consensus analysts' recommendation for Foamix Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Foamix Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Foamix Pharmaceuticals. Has Foamix Pharmaceuticals been receiving favorable news coverage? Media coverage about FOMX stock has trended somewhat positive recently, InfoTrie reports. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Foamix Pharmaceuticals earned a media sentiment score of 1.3 on InfoTrie's scale. They also gave headlines about the specialty pharmaceutical company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the company's share price in the immediate future. Are investors shorting Foamix Pharmaceuticals? Foamix Pharmaceuticals saw a increase in short interest in the month of February. As of February 28th, there was short interest totalling 2,178,410 shares, an increase of 32.3% from the February 15th total of 1,647,042 shares. Based on an average daily volume of 552,604 shares, the days-to-cover ratio is presently 3.9 days. Approximately 4.6% of the shares of the stock are sold short. View Foamix Pharmaceuticals' Current Options Chain. Who are some of Foamix Pharmaceuticals' key competitors? Some companies that are related to Foamix Pharmaceuticals include CV Sciences (CVSI), Canopy Rivers (RIV), Chromadex (CDXC), Mediwound (MDWD), Natural Alternatives International (NAII), China Jo-Jo Drugstores (CJJD), Mannatech (MTEX), Cyanotech (CYAN), GLG Life Tech (GLGLF), Tauriga Sciences (TAUG), FitLife Brands (FTLF), True Drinks (TRUU), Nutra Pharma (NPHC), Entia Biosciences (ERGO) and Rock Creek Pharmaceuticals (RCPIQ). What other stocks do shareholders of Foamix Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Foamix Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Novavax (NVAX), Gilead Sciences (GILD), Tonix Pharmaceuticals (TNXP), AcelRx Pharmaceuticals (ACRX), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Amarin (AMRN) and Sangamo Therapeutics (SGMO). Who are Foamix Pharmaceuticals' key executives? Foamix Pharmaceuticals' management team includes the folowing people: Mr. David T. Domzalski, CEO & Director (Age 52)Mr. Ilan Hadar MBA, CFO & Country Mang. (Age 50)Mr. Yohan Hazot, VP of Pharmaceutical Devel. (Age 36)Dr. Darrell S. Rigel M.D., MS, Consultant (Age 69)Ms. Mutya Harsch, Gen. Counsel & Sr. VP of Legal Affairs Who are Foamix Pharmaceuticals' major shareholders? Foamix Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (8.59%), Great Point Partners LLC (7.46%), Stonepine Capital Management LLC (2.38%), Millennium Management LLC (1.94%), Sofinnova Investments Inc. (1.53%) and BlackRock Inc. (1.14%). Company insiders that own Foamix Pharmaceuticals stock include Aharon Schwartz, Alvin D Howard, David Domzalski, Iain Stuart, Matthew T Wiley, Meir Eini, Russell P Elliott and Stanley Hirsch. View Institutional Ownership Trends for Foamix Pharmaceuticals. Which institutional investors are selling Foamix Pharmaceuticals stock? FOMX stock was sold by a variety of institutional investors in the last quarter, including D. E. Shaw & Co. Inc., Bank of New York Mellon Corp, Tekla Capital Management LLC, First Manhattan Co., Millennium Management LLC, Squarepoint Ops LLC, UBS Oconnor LLC and UBS Oconnor LLC. Company insiders that have sold Foamix Pharmaceuticals company stock in the last year include Alvin D Howard, David Domzalski, Iain Stuart, Russell P Elliott and Stanley Hirsch. View Insider Buying and Selling for Foamix Pharmaceuticals. Which institutional investors are buying Foamix Pharmaceuticals stock? FOMX stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Stonepine Capital Management LLC, Knott David M, Sofinnova Investments Inc., Diag Capital Management LP, BlackRock Inc., ETF Managers Group LLC and Eversept Partners LP. Company insiders that have bought Foamix Pharmaceuticals stock in the last two years include Aharon Schwartz and Matthew T Wiley. View Insider Buying and Selling for Foamix Pharmaceuticals. How do I buy shares of Foamix Pharmaceuticals? Shares of FOMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Foamix Pharmaceuticals' stock price today? One share of FOMX stock can currently be purchased for approximately $3.87. How big of a company is Foamix Pharmaceuticals? Foamix Pharmaceuticals has a market capitalization of $210.40 million and generates $3.60 million in revenue each year. The specialty pharmaceutical company earns $-74,160,000.00 in net income (profit) each year or ($1.70) on an earnings per share basis. What is Foamix Pharmaceuticals' official website? The official website for Foamix Pharmaceuticals is http://www.foamix.com. How can I contact Foamix Pharmaceuticals? Foamix Pharmaceuticals' mailing address is 2 HOLZMAN ST. WEIZMANN SCIENCE PARK, REHOVOT L3, 76704. The specialty pharmaceutical company can be reached via phone at 972-8931-6233 or via email at [email protected] MarketBeat Community Rating for Foamix Pharmaceuticals (NASDAQ FOMX)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 183 (Vote Outperform)Underperform Votes: 193 (Vote Underperform)Total Votes: 376MarketBeat's community ratings are surveys of what our community members think about Foamix Pharmaceuticals and other stocks. Vote "Outperform" if you believe FOMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FOMX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/20/2019 by MarketBeat.com StaffFeatured Article: How is the Producer Price Index calculated?